An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques  

作　　者：Yuanyuan Li Yanan Zhang Yu Zhou Yan Li Jiao Xu Yuanbao Ai Lei Xu Xiuli Xiao Bo Zhang Jing Jin 

机构地区：[1]Patronus Biotech Co.Ltd.,Yantai,China [2]Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,430071,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第5期2081-2084,共4页信号转导与靶向治疗（英文）

摘　　要：Dear Editor,Since early 2020,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has spread globally infecting over 500 million people and causing over 6 million deaths.The massive worldwide immunisation programmes and the arising clinical trial data present a unique opportunity to compare the vaccines and various delivery platforms(i.e.viral vector platform,mRNA platform and virus-like particle platform).

关 键 词：ACUTE RESPIRATORY particle 

分 类 号：R563.1[医药卫生—呼吸系统] R186[医药卫生—内科学]